| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,782,000 |
| Market
Cap: |
583.34(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.88 - $4.56 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
76,654 |
85,500 |
119,597 |
| Total Sell Value |
$0 |
$251,655 |
$284,292 |
$363,141 |
| Total People Sold |
0 |
4 |
5 |
6 |
| Total Sell Transactions |
0 |
4 |
5 |
9 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gline Matthew |
Director |
– • • |
2025-02-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
38,847,462 |
|
-6% |
|
| Sims Karen |
Chief Medical Officer |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
49,300 |
155,494 |
|
- |
|
| Naftzger J. Christopher |
General Counsel and CCO |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
54,300 |
140,544 |
|
- |
|
| Mcelhaugh Michael J. |
Interim President & CEO |
• • – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
177,000 |
1,658,003 |
|
- |
|
| Hastings David C |
Chief Financial Officer |
• – – |
2025-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
90,100 |
249,824 |
|
- |
|
| Naftzger J. Christopher |
General Counsel and CCO |
• – – |
2025-02-04 |
4 |
AS |
$3.28 |
$37,206 |
D/D |
(11,333) |
86,244 |
|
5% |
|
| Mcelhaugh Michael J. |
Interim President & CEO |
• • – |
2025-02-04 |
4 |
AS |
$3.28 |
$78,103 |
D/D |
(23,790) |
1,481,003 |
|
5% |
|
| Hastings David C |
Chief Financial Officer |
• – – |
2025-02-04 |
4 |
AS |
$3.28 |
$72,827 |
D/D |
(22,183) |
159,724 |
|
5% |
|
| Sims Karen |
Chief Medical Officer |
• – – |
2025-02-04 |
4 |
AS |
$3.28 |
$63,519 |
D/D |
(19,348) |
106,194 |
|
5% |
|
| Manchester Keith S |
Director |
– • – |
2024-08-14 |
4 |
S |
$3.69 |
$32,637 |
D/D |
(8,846) |
46,069 |
|
13% |
|
| Manchester Keith S |
Director |
– • – |
2024-08-14 |
4 |
OE |
$0.56 |
$30,752 |
D/D |
54,915 |
54,915 |
|
- |
|
| Sofia Michael J. |
Chief Scientific Officer |
• – – |
2024-02-02 |
4 |
AS |
$2.31 |
$23,083 |
D/D |
(9,982) |
1,485,121 |
|
33% |
|
| Hastings David C |
Chief Financial Officer |
• – – |
2024-02-02 |
4 |
AS |
$2.31 |
$22,184 |
D/D |
(9,593) |
181,907 |
|
33% |
|
| Mcelhaugh Michael J. |
Interim President & CEO |
• • – |
2024-02-02 |
4 |
AS |
$2.31 |
$23,504 |
D/D |
(10,164) |
1,504,793 |
|
33% |
|
| Sims Karen |
Chief Medical Officer |
• – – |
2024-02-02 |
4 |
AS |
$2.31 |
$10,078 |
D/D |
(4,358) |
125,542 |
|
33% |
|
| Sofia Michael J. |
Chief Scientific Officer |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
109,500 |
1,495,103 |
|
- |
|
| Naftzger J. Christopher |
General Counsel and CCO |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
95,100 |
95,100 |
|
- |
|
| Hastings David C |
Chief Financial Officer |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
112,500 |
191,500 |
|
- |
|
| Mcelhaugh Michael J. |
Interim President & CEO |
• • – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
123,800 |
1,514,957 |
|
- |
|
| Sims Karen |
Chief Medical Officer |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
101,000 |
129,900 |
|
- |
|
| Sims Karen |
Chief Medical OfficerOfficer |
• – – |
2023-07-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,900 |
|
-17% |
|
| Hastings David C |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
79,000 |
79,000 |
|
- |
|
| Collier William H. |
President and CEO |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
216,500 |
216,500 |
|
- |
|
| Howard Elizabeth |
EVP, GC, Compliance |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
69,700 |
86,024 |
|
- |
|
| Mcelhaugh Michael J. |
Chief Business Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
83,700 |
1,391,157 |
|
- |
|
54 Records found
|
|
Page 1 of 3 |
|
|
0.04 (1.28%) 
